Clara Burtenshaw, Neo Kuma Ventures, on shattering the stigma of psychedelic medication
pulsepodcastbywharton.substack.com
In this episode, we sat down with Clara Burtenshaw, Partner and Investor at Neo Kuma Ventures. Neo Kuma Ventures is the first psychedelics-focused venture capital fund in Europe. Clara is a biotech and life sciences investor with significant transactional, VC, IP, and operational experience. Prior to founding Neo Kuma Ventures, she served as General Counsel at a PE-backed major retail group, growing revenue to £365M through M&A, international rollouts and restructuring. Clara began her career at
Clara Burtenshaw, Neo Kuma Ventures, on shattering the stigma of psychedelic medication
Clara Burtenshaw, Neo Kuma Ventures, on…
Clara Burtenshaw, Neo Kuma Ventures, on shattering the stigma of psychedelic medication
In this episode, we sat down with Clara Burtenshaw, Partner and Investor at Neo Kuma Ventures. Neo Kuma Ventures is the first psychedelics-focused venture capital fund in Europe. Clara is a biotech and life sciences investor with significant transactional, VC, IP, and operational experience. Prior to founding Neo Kuma Ventures, she served as General Counsel at a PE-backed major retail group, growing revenue to £365M through M&A, international rollouts and restructuring. Clara began her career at